Company intelligence / Profile preview

Rapport Therapeutics

boston_headquarters_cited_in_press_releases[5][10], multiple_locations_suggested_by_press_releases, United Statesrapportrx.com ↗

Overview

Lead candidate RAP-219 shows neuroanatomical specificity through TARPγ8 targeting[5][10]
Phase1 PET/MAD-2 trials demonstrated target engagement and favorable tolerability in healthy subjects[5][10]
Phase2a epilepsy trial on track for Q3'25 topline results[5][6]

4 assets

3 more assets in the full pipeline.

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Rapport Therapeutics.